Anne Banos

4.3k total citations
27 papers, 261 citations indexed

About

Anne Banos is a scholar working on Hematology, Genetics and Pathology and Forensic Medicine. According to data from OpenAlex, Anne Banos has authored 27 papers receiving a total of 261 indexed citations (citations by other indexed papers that have themselves been cited), including 19 papers in Hematology, 14 papers in Genetics and 11 papers in Pathology and Forensic Medicine. Recurrent topics in Anne Banos's work include Chronic Lymphocytic Leukemia Research (13 papers), Lymphoma Diagnosis and Treatment (11 papers) and Acute Myeloid Leukemia Research (9 papers). Anne Banos is often cited by papers focused on Chronic Lymphocytic Leukemia Research (13 papers), Lymphoma Diagnosis and Treatment (11 papers) and Acute Myeloid Leukemia Research (9 papers). Anne Banos collaborates with scholars based in France, Greece and United States. Anne Banos's co-authors include Pierre Fenaux, Michel Blanc, Norbert Vey, Guillaume Cartron, Kevin Song, Lionel Karlin, Michel Delforge, Mohamed H. Zaki, Philippe Moreau and Caroline Besson and has published in prestigious journals such as Journal of Clinical Oncology, Blood and British Journal of Haematology.

In The Last Decade

Anne Banos

25 papers receiving 253 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Anne Banos France	10	167	127	81	73	57	27	261
José Antonio Queizán Spain	7	103 0.6×	74 0.6×	48 0.6×	58 0.8×	26 0.5×	13	169
Raouf Ben Abdelali France	8	145 0.9×	74 0.6×	41 0.5×	55 0.8×	79 1.4×	15	262
Jaclyn Cordero United States	6	209 1.3×	204 1.6×	133 1.6×	143 2.0×	81 1.4×	10	343
Silja Mack Germany	4	158 0.9×	41 0.3×	89 1.1×	63 0.9×	52 0.9×	6	265
Seo-Yeon Ahn South Korea	7	123 0.7×	51 0.4×	47 0.6×	73 1.0×	21 0.4×	26	215
C. Troff Germany	7	224 1.3×	77 0.6×	91 1.1×	57 0.8×	51 0.9×	13	301
Serena Rocchi Italy	9	255 1.5×	180 1.4×	33 0.4×	157 2.2×	26 0.5×	31	301
Alessandra Scardocci Italy	8	165 1.0×	324 2.6×	42 0.5×	67 0.9×	42 0.7×	9	402
Janet Briel United States	6	165 1.0×	160 1.3×	43 0.5×	104 1.4×	14 0.2×	7	318
Michaël Broux Belgium	6	114 0.7×	128 1.0×	30 0.4×	55 0.8×	48 0.8×	6	277

Countries citing papers authored by Anne Banos

Since Specialization

Citations

This map shows the geographic impact of Anne Banos's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Anne Banos with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Anne Banos more than expected).

Fields of papers citing papers by Anne Banos

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Anne Banos. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Anne Banos. The network helps show where Anne Banos may publish in the future.

Co-authorship network of co-authors of Anne Banos

This figure shows the co-authorship network connecting the top 25 collaborators of Anne Banos. A scholar is included among the top collaborators of Anne Banos based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Anne Banos. Anne Banos is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Bertoli, Sarah, Maël Heiblig, Thibaut Leguay, et al.. (2024). Real-World Multicenter Comparison of Venetoclax and Azacitidine Versus Intermediate or High Dose Cytarabine-Based Salvage for Patients with AML in First Relapse after Front Line Intensive Chemotherapy. a Dataml-IPC-Auraml Consortium Study. Blood. 144(Supplement 1). 4275–4275.

Lamy, Thierry, Cédric Pastoret, Gandhi Damaj, et al.. (2024). Prospective, Multicentric, Phase II Randomized Controlled Trial Comparing the Efficacy and Toxicity of Methotrexate to Cyclophosphamide in Large Granular Lymphocyte Leukemia: A French National Study (NCT01976182). Blood. 144(Supplement 1). 979–979. 2 indexed citations

Cazaubiel, Titouan, Anne Banos, M. Carreiro, et al.. (2024). Real-World Multicenter Data of Venetoclax Use in Multiple Myeloma with t(11-14). Time to Consider It Again. Blood. 144(Supplement 1). 7030–7030.

Botton, Stéphane de, Thomas Cluzeau, Carlos E. Vigil, et al.. (2020). SY-1425, a Potent and Selective RARα Agonist, in Combination with Azacitidine Demonstrates a High Complete Response Rate and a Rapid Onset of Response in RARA-Positive Newly Diagnosed Unfit Acute Myeloid Leukemia. Blood. 136(Supplement 1). 4–5. 6 indexed citations

Ysebaert, Loïc, Lucie Obéric, Anne Banos, et al.. (2019). Oncology nurse phone calls halve the risk of reduced dose intensity of immunochemotherapy: results of the randomized FORTIS study in chronic lymphocytic leukemia.. Annals of Hematology. 98(4). 931–939. 7 indexed citations

Gagez, Anne-Laure, Isabelle Duroux-Richard, Stéphane Leprêtre, et al.. (2017). miR-125b and miR-532-3p predict the efficiency of rituximab-mediated lymphodepletion in chronic lymphocytic leukemia patients. A French Innovative Leukemia Organization study. Haematologica. 102(4). 746–754. 21 indexed citations

Lamy, T., Gandhi Damaj, Emmanuel Gyan, et al.. (2014). R-CHOP with or without Radiotherapy in Non-Bulky Limited-Stage Diffuse Large B Cell Lymphoma (DLBCL): Preliminary Results of the Prospective Randomized Phase III 02-03 Trial from the Lysa/Goelams Group. Blood. 124(21). 393–393. 17 indexed citations

Leleu, Xavier, Steven Le Gouill, Lionel Karlin, et al.. (2014). Lenalidomide Is Safe and Active in Waldenstrom Macroglobulinemia (WM). Blood. 124(21). 4478–4478. 3 indexed citations

Abdelali, Raouf Ben, Anne Roggy, Thibaut Leguay, et al.. (2014). SET-NUP214 is a recurrent γδ lineage-specific fusion transcript associated with corticosteroid/chemotherapy resistance in adult T-ALL. Blood. 123(12). 1860–1863. 36 indexed citations

10.

Miguel, Jesús F. San, Katja Weisel, Philippe Moreau, et al.. (2013). MM-003: A phase III, multicenter, randomized, open-label study of pomalidomide (POM) plus low-dose dexamethasone (LoDEX) versus high-dose dexamethasone (HiDEX) in relapsed/refractory multiple myeloma (RRMM).. Journal of Clinical Oncology. 31(15_suppl). 8510–8510. 5 indexed citations

11.

Leblond, Véronique, Sylvie Chevret, Xavier Leleu, et al.. (2013). Phase II Trial In Advanced Waldenstrom Macroglobulinemia (WM) Patients With Bortezomib: Interest Of Addition Of Dexamethasone To Bortezomib On Behalf Of The French CLL/WM Intergroup (NCT 00777738). Blood. 122(21). 4359–4359. 2 indexed citations

12.

Song, Kevin, Meletios Α. Dimopoulos, Katja Weisel, et al.. (2013). Quality of life (QOL) improvements for pomalidomide plus low-dose dexamethasone (POM + LoDEX) in relapsed and refractory multiple myeloma (RRMM) patients (pts) enrolled in MM-003.. Journal of Clinical Oncology. 31(15_suppl). 8583–8583. 2 indexed citations

13.

Gyan, Emmanuel, Diane Damotte, Delphine Sénécal, et al.. (2013). High response rate and acceptable toxicity of a combination of rituximab, vinorelbine, ifosfamide, mitoxantrone and prednisone for the treatment of diffuse large B‐cell lymphoma in first relapse: results of the R‐NIMP GOELAMS study. British Journal of Haematology. 162(2). 240–249. 13 indexed citations

14.

Toma, Andréa, Sylvie Chevret, Olivier Kosmider, et al.. (2013). A randomized study of lenalidomide (LEN) with or without EPO in RBC transfusion dependent (TD) IPSS low and int-1 (lower risk) myelodysplastic syndromes (MDS) without del 5q resistant to EPO.. Journal of Clinical Oncology. 31(15_suppl). 7002–7002. 10 indexed citations

15.

Weisel, Katja, Meletios Α. Dimopoulos, Philippe Moreau, et al.. (2013). Pomalidomide plus low-dose dexamethasone (POM + LoDEX) versus high-dose dexamethasone (HiDEX) in relapsed/refractory multiple myeloma (RRMM): MM-003 analysis of patients (pts) with moderate renal impairment (RI).. Journal of Clinical Oncology. 31(15_suppl). 8527–8527. 12 indexed citations

16.

Dimopoulos, Meletios Α., Martha Q. Lacy, Philippe Moreau, et al.. (2012). Pomalidomide in Combination with Low-Dose Dexamethasone: Demonstrates a Significant Progression Free Survival and Overall Survival Advantage, in Relapsed/Refractory MM: A Phase 3, Multicenter, Randomized, Open-Label Study. Blood. 120(21). LBA–6. 28 indexed citations

17.

Sibon, David, Giovanna Cannas, Thomas Prébet, et al.. (2011). Lenalidomide in lower‐risk myelodysplastic syndromes with karyotypes other than deletion 5q and refractory to erythropoiesis‐stimulating agents. British Journal of Haematology. 156(5). 619–625. 29 indexed citations

18.

Bras, Fabien Le, Charikleia Kelaïdi, Thierry Lamy, et al.. (2011). Treatment by Lenalidomide in lower risk myelodysplastic syndrome with 5q deletion—The GFM experience. Leukemia Research. 35(11). 1444–1448. 28 indexed citations

19.

Sibon, David, Giovanna Cannas, Fiorenza Barraco, et al.. (2010). Lenalidomide (LEN) In Lower-Risk Myelodysplastic Syndromes (MDS) with Karyotypes Other Than Deletion 5q and Refractory to Erythropoiesis-Stimulating Agents (ESAs). Blood. 116(21). 4002–4002. 2 indexed citations

20.

Parrens, Marie, et al.. (2006). Granulomatose lymphomatoïde dans les suites d’une leucémie aiguë myéloïde. Annales de Pathologie. 26(1). 22–25. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact